Sudeep Pharma Limited Share Price & Analysis
Price Chart
Fundamentals
Strengths
- Excellent return on equity (ROE 25.2%)
- Efficient capital deployment (ROCE 28.2%)
- Low debt relative to equity (D/E 0.2x)
Concerns
- High premium to book value (P/B 11.7x)
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,758 | ₹4.2L Cr | 33.2 | 5.05 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹9,559 | ₹2.4L Cr | 79.8 | 15.15 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹4,557 | ₹1.7L Cr | 79.3 | 9.43 | 27.4 | 15.2 | 0.77 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,176 | ₹1.1L Cr | 23.1 | 4.37 | 21.2 | 21.1 | 0.38 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,137 | ₹1.1L Cr | 52.8 | 12.35 | 21.2 | 17.4 | 0.88 |
| CIPLA Cipla Limited | ₹1,366 | ₹1.1L Cr | 30.2 | 3.21 | 11.6 | 15.5 | 0.01 |
| LAURUSLABS Laurus Labs Limited | ₹2,182 | ₹1.1L Cr | 97.4 | 22.22 | 18.3 | 17.8 | 0.46 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
SUDEEPPHRM · as of Sep 2026
| Category | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Promoters | 76.16% | 76.16% | 76.16% | 76.16% |
| FII | 1.67% | 1.55% | 1.81% | 2.93% |
| DII | 17.59% | 18.11% | 15.64% | 14.06% |
| Public | 4.57% | 4.18% | 6.39% | 6.87% |
Corporate Events
To consider and approve the financial results for the period ended September 30, 2026 and other business matters
To consider and approve the financial results for the period ended Jun 30, 2026 and other business matters
Dividend - Rs 1.50 Per Share
Latest News
All newsSudeep Pharma gets FDA nod for Gujarat facility
*Sudeep Pharma gets FDA nod for Gujarat facility* — Sudeep Pharma announced FDA approval for its new greenfield manufacturing plant at 179 Nandesari, Gujarat. The clearance boosts export potential to the US market. Facility launch may add **₹200Cr** to revenue in 3 years. Expansion aligns with rising global demand for Indian generics. 📊 *STOCKS:* $SUDEEPPHARMA | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #FDA
Sudeep Pharma's FDA nod starts Gujarat plant ops
*Sudeep Pharma's FDA approval enables operations at its new greenfield facility in Nandesari, Gujarat.* This clears regulatory hurdles and marks a strategic expansion in its manufacturing footprint. The facility launch supports increased production capacity and future revenue growth. 📊 *STOCKS:* $SUDEEPPHARM | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #Pharma
Sudeep Pharma to host analyst and investor meet
*Sudeep Pharma to host an analyst and investor conference call.* The event aims to provide updates on company performance and strategy. Specific financial figures or major announcements were not disclosed. Details of the schedule are available in the NSE filing. 📊 *STOCKS:* SUDEEPPHARMA | 🏢 *SECTOR:* Pharma | #LOWIMPACT #InvestorMeet
Sudeep Pharma to host investor meet
*Sudeep Pharma to host an analyst and institutional investor meet.* The company will share updates on business performance and strategy during the call. **No financial figures or major announcements** were disclosed in the filing. The event is scheduled as part of regular investor outreach. 📊 *STOCKS:* $SUDEEP | 🏢 *SECTOR:* Pharma | #LOWIMPACT #InvestorMeet
Sudeep Pharma to host investor meet
*Sudeep Pharma to host an analyst and institutional investor meet.* The event aims to provide updates on company performance and future outlook. Specific financial figures or strategic announcements were not disclosed. Investors await further clarity on growth plans. 📊 *STOCKS:* $SUDEEPPHARM | 🏢 *SECTOR:* Pharma | #LOWIMPACT #InvestorMeet
Sudeep Pharma to host investor meet for updates
*Sudeep Pharma to host investor meet for updates.* The company has scheduled an analyst and institutional investor meet to discuss business developments. No financial figures or major announcements were disclosed. This event is informational ahead of future disclosures. 📊 *STOCKS:* $SUDEEPPHARM | 🏢 *SECTOR:* Pharma | #LOWIMPACT #InvestorMeet
Sudeep Pharma holds AGM, shares voting results
*Sudeep Pharma holds AGM, shares voting results*. Sudeep Pharma Limited disclosed the scrutinizer's report of its Annual General Meeting held on **August 04, 2026**. The company shared voting results with the exchange as part of regulatory compliance. No material business decisions or financial updates were announced. 📊 *STOCKS:* $SUDEEPHPHARMA | 🏢 *SECTOR:* Pharma | #LOWIMPACT #AGM
Sudeep Pharma publishes mandatory newspaper notice
*Sudeep Pharma publishes mandatory newspaper notice.* This is a routine regulatory disclosure as required by corporate filing norms. No financial or operational updates were included. Such notices typically relate to board meetings or shareholder communications. 📊 *STOCKS:* $SUDEEPPHARM | 🏢 *SECTOR:* Pharma | #LOWIMPACT #CorporateFiling
Sudeep Pharma sets dividend record date for July 2026
*Sudeep Pharma sets dividend record date for July 2026.* The company has informed the exchange that the record date for dividend distribution is fixed at **23-Jul-2026**. This allows shareholders to determine eligibility for the proposed dividend. No details on dividend amount or payment date have been disclosed yet. 📊 *STOCKS:* SUDEEP | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Dividend
Sudeep Pharma releases annual report for FY25-26
*Sudeep Pharma releases annual report for FY25-26* — The company has shared its Integrated Annual Report with shareholders, detailing operational and financial performance. No major financial updates or strategic shifts were highlighted. The filing is part of routine corporate disclosure requirements. 📊 *STOCKS:* SUDEEPPHARM | 🏢 *SECTOR:* Pharma | #LOWIMPACT #AnnualReport
Financials
Quarterly Results
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹158 Cr 13.2% | ₹182 Cr 5.8% | ₹172 Cr 5.5% | ₹163 Cr 30.4% | ₹125 Cr 20.9% | ₹158 Cr 36.2% | ₹116 Cr 22.1% | ₹149 Cr |
| Op. Profit | ₹55 Cr 12.7% | ₹63 Cr 5.0% | ₹60 Cr 9.1% | ₹55 Cr 25.0% | ₹44 Cr 25.4% | ₹59 Cr 51.3% | ₹39 Cr 38.1% | ₹63 Cr |
| OPM | 35.0% 2.9% | 34.0% 2.9% | 35.0% 2.9% | 34.0% 2.9% | 35.0% 5.4% | 37.0% 8.8% | 34.0% 20.9% | 43.0% |
| Net Profit | ₹41 Cr 16.3% | ₹49 Cr 2.1% | ₹48 Cr 2.1% | ₹47 Cr 51.6% | ₹31 Cr 29.5% | ₹44 Cr 51.7% | ₹29 Cr 40.8% | ₹49 Cr |
| EPS (₹) | 3.59 17.1% | 4.33 3.1% | 4.2 10.8% | 4.71 48.6% | 3.17 30.2% | 4.54 53.9% | 2.95 49.1% | 5.8 |
Values in ₹ Cr · Source: Screener.in
Annual Profit & Loss
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | ₹642 Cr 27.9% | ₹502 Cr 9.4% | ₹459 Cr 7.0% | ₹429 Cr 25.1% | ₹343 Cr 59.5% | ₹215 Cr 74.8% | ₹123 Cr |
| Expenses | ₹419 Cr 35.2% | ₹310 Cr 12.3% | ₹276 Cr 18.3% | ₹338 Cr 22.5% | ₹276 Cr 61.4% | ₹171 Cr 74.5% | ₹98 Cr |
| Op. Profit | ₹223 Cr 16.1% | ₹192 Cr 4.9% | ₹183 Cr 103.3% | ₹90 Cr 34.3% | ₹67 Cr 52.3% | ₹44 Cr 76.0% | ₹25 Cr |
| OPM | 35.0% 7.9% | 38.0% 5.0% | 40.0% 90.5% | 21.0% 5.0% | 20.0% 0.0% | 20.0% 4.8% | 21.0% |
| Other Income | ₹28 Cr 211.1% | ₹9 Cr 50.0% | ₹6 Cr 33.3% | ₹9 Cr 28.6% | ₹7 Cr 133.3% | ₹3 Cr 0.0% | ₹3 Cr |
| Interest | ₹8 Cr 14.3% | ₹7 Cr 40.0% | ₹5 Cr 16.7% | ₹6 Cr 200.0% | ₹2 Cr 100.0% | ₹1 Cr 0.0% | ₹1 Cr |
| Depreciation | ₹15 Cr 36.4% | ₹11 Cr 22.2% | ₹9 Cr 12.5% | ₹8 Cr 60.0% | ₹5 Cr 25.0% | ₹4 Cr 33.3% | ₹3 Cr |
| PBT | ₹228 Cr 24.6% | ₹183 Cr 4.6% | ₹175 Cr 103.5% | ₹86 Cr 24.6% | ₹69 Cr 60.5% | ₹43 Cr 72.0% | ₹25 Cr |
| Tax % | 24.0% 0.0% | 24.0% 0.0% | 24.0% 14.3% | 28.0% 3.7% | 27.0% 22.7% | 22.0% 18.5% | 27.0% |
| Net Profit | ₹174 Cr 25.2% | ₹139 Cr 4.5% | ₹133 Cr 114.5% | ₹62 Cr 24.0% | ₹50 Cr 51.5% | ₹33 Cr 83.3% | ₹18 Cr |
| EPS (₹) | 15.31 7.3% | 14.27 10.0% | 15.86 113.7% | 7.42 24.3% | 5.97 50.4% | 3.97 84.7% | 2.15 |
| Div Payout | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Values in ₹ Cr · Source: Screener.in
Balance Sheet
| Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|---|---|
Liabilities | |||||||
| Equity Capital | ₹11 Cr 10.0% | ₹10 Cr 900.0% | ₹1 Cr 0.0% | ₹1 Cr 0.0% | ₹1 Cr 0.0% | ₹1 Cr 0.0% | ₹1 Cr |
| Reserves | ₹872 Cr 81.3% | ₹481 Cr 35.5% | ₹355 Cr 59.9% | ₹222 Cr 37.0% | ₹162 Cr 43.4% | ₹113 Cr 41.3% | ₹80 Cr |
| Borrowings | ₹150 Cr 7.1% | ₹140 Cr 79.5% | ₹78 Cr 6.0% | ₹83 Cr 1.2% | ₹84 Cr 171.0% | ₹31 Cr 55.0% | ₹20 Cr |
| Other Liabilities | ₹141 Cr 64.0% | ₹86 Cr 7.5% | ₹80 Cr 29.2% | ₹113 Cr 16.5% | ₹97 Cr 44.8% | ₹67 Cr 123.3% | ₹30 Cr |
| Total Liabilities | ₹1.2K Cr 63.7% | ₹717 Cr 39.5% | ₹514 Cr 22.4% | ₹420 Cr 22.1% | ₹344 Cr 61.5% | ₹213 Cr 62.6% | ₹131 Cr |
Assets | |||||||
| Fixed Assets | ₹337 Cr 78.3% | ₹189 Cr 5.0% | ₹180 Cr 13.9% | ₹158 Cr 15.3% | ₹137 Cr 101.5% | ₹68 Cr 13.3% | ₹60 Cr |
| CWIP | ₹185 Cr 110.2% | ₹88 Cr 95.6% | ₹45 Cr 73.1% | ₹26 Cr 225.0% | ₹8 Cr 66.7% | ₹24 Cr 200.0% | ₹8 Cr |
| Investments | ₹0 Cr | ₹0 Cr | ₹0 Cr 100.0% | ₹3 Cr | ₹0 Cr 100.0% | ₹19 Cr 216.7% | ₹6 Cr |
| Other Assets | ₹652 Cr 48.5% | ₹439 Cr 51.9% | ₹289 Cr 24.6% | ₹232 Cr 16.6% | ₹199 Cr 95.1% | ₹102 Cr 78.9% | ₹57 Cr |
| Total Assets | ₹1.2K Cr 63.7% | ₹717 Cr 39.5% | ₹514 Cr 22.4% | ₹420 Cr 22.1% | ₹344 Cr 61.5% | ₹213 Cr 62.6% | ₹131 Cr |
Values in ₹ Cr · Source: Screener.in
Cash Flow Statement
| Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|---|---|
| Operating CF | ₹70 Cr 42.9% | ₹49 Cr 25.8% | ₹66 Cr 37.5% | ₹48 Cr 1700.0% | ₹-3 Cr 108.6% | ₹35 Cr 250.0% | ₹10 Cr |
| Investing CF | ₹-327 Cr 313.9% | ₹-79 Cr 61.2% | ₹-49 Cr 2.0% | ₹-50 Cr 31.6% | ₹-38 Cr 5.0% | ₹-40 Cr 81.8% | ₹-22 Cr |
| Financing CF | ₹247 Cr 366.0% | ₹53 Cr 507.7% | ₹-13 Cr 30.0% | ₹-10 Cr 119.6% | ₹51 Cr 292.3% | ₹13 Cr 8.3% | ₹12 Cr |
| Net Cash Flow | ₹-10 Cr 143.5% | ₹23 Cr 475.0% | ₹4 Cr 136.4% | ₹-11 Cr 210.0% | ₹10 Cr 25.0% | ₹8 Cr | ₹0 Cr |
| Free Cash Flow | ₹-49 Cr 226.7% | ₹-15 Cr 215.4% | ₹13 Cr 1200.0% | ₹1 Cr 101.3% | ₹-77 Cr 420.8% | ₹24 Cr 2300.0% | ₹1 Cr |
Values in ₹ Cr · Source: Screener.in
Key Ratios History
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|---|---|
| Debtor Days | 129d 4.4% | 135d 17.4% | 115d 43.8% | 80d 29.8% | 114d 21.3% | 94d 4.4% | 90d |
| Inventory Days | 356d 15.2% | 309d 110.2% | 147d 3.5% | 142d 36.5% | 104d 31.6% | 79d 2.6% | 77d |
| Days Payable | 113d 22.1% | 145d 29.5% | 112d 45.5% | 77d 1.3% | 76d 3.8% | 79d 12.9% | 70d |
| Cash Conv. Cycle | 372d 24.8% | 298d 98.7% | 150d 3.4% | 145d 2.1% | 142d 52.7% | 93d 4.1% | 97d |
| Working Capital Days | 175d 21.5% | 144d 45.5% | 99d 7.6% | 92d 206.7% | 30d 130.8% | 13d 71.7% | 46d |
| ROCE | 28.0% 22.2% | 36.0% 26.5% | 49.0% 48.5% | 33.0% 8.3% | 36.0% 0.0% | 36.0% | — |
Source: Screener.in · Lower days = better efficiency